The year 2020 presented us with major challenges. We are happy to announce that we obtained freedom-to-operate in Europe for the first multiplex assay to classify breast cancer. Ongoing projects include analysis of FFPE biopsies, xenograft classification, exosome research and many more.
Join us in our mission:
To synergise the advantages of microfluidics, and multiplex bead based assays, to measure biomarkers in blood-derived exosomes
To develop a molecular test that measures COVID-19 (SARS-CoV-2) immune response for vaccine surveillance.
To innovate a companion diagnostic product that predicts use of specific therapeutics in Epilepsy.